ALNY - Alnylam Stock: Undervalued Heading Into A Catalyst-Rich Year

• Alnylam has multiple clinical read-outs coming over the next 12 months that can meaningfully drive the shares, including the APOLLO-B study in mid-22.
• Zilebesiran is the highest-potential drug that I see in the pipeline today, with Phase II monotherapy data due before year-end.
• Strong Phase II data from other compounds could likewise add meaningful value, and Alnylam has active preclinical development programs that should go into the clinic in 2023+.
• Below $195/share, I believe ALNY stock is well worth consideration from investors willing and able to take the risks of biotech investing.

For further details see: